David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Add Gevo Stock to Your Sustainability-Focused Holdings Once Prices Lower

By David Moadel, InvestorPlace Contributor

GEVO stock is down from its peak price, and this may catch value investors' attention. Yet, the data appears to signal a need for caution.

Sundial Growers Is Bound to Be a Surprise Summer Hit

By David Moadel, InvestorPlace Contributor

SNDL stock went from a meme favorite to a forgotten treasure in the cannabis space. The stock's decline presents an opportunity.

Invest in Growth-Oriented Tech with Invesco QQQ ETF

By David Moadel, InvestorPlace Contributor

Whether for a short-term trade or a long-term investment, you can position yourself quickly in the technology sector with QQQ stock.

Bull Thesis for Workhorse Group Is That Things Can’t Get Much Worse

By David Moadel, InvestorPlace Contributor

The fiscal results are in and they're quite grim - yet, contrarians may find an opportunity in the negative sentiment surrounding WKHS stock.

Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma

By David Moadel, InvestorPlace Contributor

A buying opportunity is here as COCP stock is down, even as Cocrystal makes progress in developing a potentially lifesaving antiviral drug.

Load More